ArticleCurrent neurovascular research2026
Multimodal MRI Combined with Cognitive Evaluation Reveals Glymphatic System Impairment in Moyamoya Vasculopathy.
Article in Current neurovascular research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe aim of this research is to fully assess glymphatic system impairment in moyamoya vasculopathy (MMV) patients with a set of multi-modal MRI biomarkers that capture crucial functional processes: cerebrospinal fluid (CSF) influx, interstitial fluid exchange (free water in white matter, FW-WM), and downstream metabolite efflux (diffusion tensor imaging along the perivascular space, DTI-ALPS), and to explore their association with cognitive performance. MATERIALS AND
methodsIn this case-control study, 22 patients with MMV and 22 healthy controls (HCs) underwent 3T MRI with T1-weighted imaging and diffusion tensor imaging (DTI), as well as the Montreal Cognitive Assessment (MoCA). Total intracranial volume (ICV), choroid plexus volume (CPV), and CSF volume were quantified, with CPV/ICV and CSF/ICV ratios subsequently derived from these volumetric measurements. The FW-WM and DTI-ALPS indices were also calculated from DTI datasets. We further performed group-wise comparisons of all biomarkers and analyzed their correlations with MoCA-assessed cognitive performance.
resultsMMV patients displayed impairments across multiple stages of the glymphatic pathway. CSF inflow was elevated, reflected by significantly increased CPV/ICV (0.157 ± 0.039% vs. 0.122 ± 0.033%, p = 0.002) and CSF/ICV (23.29 ± 2.73% vs. 20.70 ± 2.22%, p < 0.001). The FW-WM of MMV was significantly higher than that of HCs (0.20 ± 0.04 vs. 0.16 ± 0.02, p < 0.001). The ALPS index of MMV was significantly lower than that of HCs (1.31 ± 0.12 vs. 1.49 ± 0.06, p < 0.001). High intercorrelations between these biomarkers (p < 0.05) supported a systemic disturbance. Cognitive performance positively correlated with the ALPS index (r = 0.588, p = 0.004) and negatively with FW-WM, CPV/ICV, and CSF/ICV (r = -0.441 to -0.661, p < 0.05). DISCUSSION: The results suggest a broad impairment of the glymphatic system across multiple functional stages in MMV, which is associated with cognitive decline.
conclusionMultimodal MRI reveals extensive changes in the glymphatic system of MMV patients, including increased CSF inflow, disrupted interstitial fluid exchange, and impaired clearance. These findings together could account for the cognitive impairments observed in this patient population.
Indexed as
Identifiers
41863410What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.